B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 1.81 NOK 1% Market Closed
Market Cap: 70.8m NOK

Bergenbio ASA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bergenbio ASA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Revenue
kr848k
CAGR 3-Years
3%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Revenue
kr257.4m
CAGR 3-Years
43%
CAGR 5-Years
31%
CAGR 10-Years
29%
L
Lytix Biopharma AS
OSE:LYTIX
Revenue
kr4m
CAGR 3-Years
N/A
CAGR 5-Years
64%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Revenue
kr104.4m
CAGR 3-Years
-7%
CAGR 5-Years
18%
CAGR 10-Years
12%
N
Nykode Therapeutics ASA
OSE:NYKD
Revenue
$8.7m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Bergenbio ASA
Glance View

Market Cap
70.7m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 89%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Revenue?
Revenue
848k NOK

Based on the financial report for Dec 31, 2024, Bergenbio ASA's Revenue amounts to 848k NOK.

What is Bergenbio ASA's Revenue growth rate?
Revenue CAGR 5Y
-38%

Over the last year, the Revenue growth was 140%. The average annual Revenue growth rates for Bergenbio ASA have been 3% over the past three years , -38% over the past five years .

Back to Top